文献速递淋巴瘤

阿替利珠单抗治疗复发/难治性结外NK/T细胞淋巴瘤的2期ATTACK试验

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.
PubMed 文献 · Blood Adv · 2026-01-01

这项多中心单臂2期研究评估阿替利珠单抗单药治疗复发/难治性结外NK/T细胞淋巴瘤的疗效与安全性。中位随访24.9个月,中位缓解持续时间未达到,中位无进展生存期和总生存期分别为2.4个月和10.3个月。

要点

  • 阿替利珠单抗单药在复发/难治性ENKTL中客观缓解率54%(7/13),完全缓解率31%(4/13)。
  • 中位随访24.9个月,中位缓解持续时间未达到,中位PFS 2.4个月,中位OS 10.3个月。
  • PD-L1结构变异或PD-L1表达阳性者缓解率更高,可能为预测生物标志物。

核心结论

  • 阿替利珠单抗在复发/难治性ENKTL中显示具有临床意义的疗效,且缓解持久。
  • PD-L1基因改变和/或PD-L1表达水平可能预测患者对该治疗的缓解。

研究设计与样本

  • 多中心、单臂2期研究(NCCH1903/ATTACK试验),评估阿替利珠单抗单药治疗复发/难治性ENKTL。

主要发现

  • 13例可评估缓解者中位年龄72岁(范围27-80),女性占46%,ECOG体能状态1分者占77%。
  • 独立评审委员会评估的客观缓解率为54%(7/13),其中完全缓解4例(31%)。
  • 中位随访24.9个月,中位缓解持续时间未达到,中位无进展生存期2.4个月,中位总生存期10.3个月。
  • 11例可评估者中4例(36%)检测到PD-L1结构变异,该组客观缓解率75%(3/4),无结构变异者客观缓解率43%(3/7)。
  • 11例可评估者中5例(45%)PD-L1表达阳性,该组客观缓解率80%(4/5),阴性者33%(2/6)。

临床怎么用

  • 对于复发/难治性ENKTL患者,阿替利珠单抗单药可作为一种治疗选择。
  • 治疗前可考虑检测PD-L1结构变异和PD-L1表达,以辅助预测缓解可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extranodal natural killer/T-cell lymphoma (ENKTL) is rare, and treatment options for relapsed/refractory (R/R) disease are limited. This multicenter, single-arm phase 2 study evaluated the efficacy and safety of atezolizumab monotherapy in patients with R/R ENKTL. The primary end point was objective response rate (ORR), as assessed by an independent review committee (IRC). Fourteen patients were ultimately enrolled. Among the 13 with evaluable responses, the median age was 72 years (range, 27-80), 46% were female, and 77% had an Eastern Cooperative Oncology Group performance status of 1. The IRC-assessed ORR was 54% (7/13), including 4 complete responses (31%). Over a median follow-up period of 24.9 months, the median duration of response was not reached. Median progression-free survival and overall survival were 2.4 and 10.3 months, respectively. Structural variations (SVs) in programmed cell death ligand 1 (PD-L1) were detected in 4 of 11 evaluable patients (36%) by targeted-capture sequencing and/or fluorescence in situ hybridization. The ORR in those patients was 75% (3/4), whereas 3 of 7 patients without PD-L1 SVs responded (ORR, 43%). PD-L1 expression was positive in 5 of 11 evaluable patients (45%) by immunohistochemistry. The ORR in that group was 80% (4/5) vs 33% (2/6) in those without PD-L1 expression. Atezolizumab demonstrated clinically meaningful efficacy with durable responses in patients with R/R ENKTL. PD-L1 genetic alterations and/or PD-L1 expression levels may represent predictive biomarkers of patient response to this approach. This trial was registered at the Japan Registry of Clinical Trials (jRCT2031190177).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Makita S, Koya J, Suzuki Y, et al. Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial. Blood Adv. 2026. PMID: 42160759. doi:10.1182/bloodadvances.2026019929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。